ALLO
Allogene Therapeutics, Inc.
$1.90
+1.06%
$655.8M
No data for this timeframe.
Vol
Market Cap$655.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders50 funds
Inst. Value$198.8M
Inst. Activity25 buys / 1 sells
Insider Activity0B / 11S
Insider Net $-$515.2K
SEC Reports8
Press Releases7
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001737287·Prev Close $1.88
Recent Activity
Jun 12, 2026
short_volume
Short Volume: ALLO — 56.7% short (3.6M / 6.3M)
Short: 3,559,817 | Exempt: 38,492 | TRF Vol: 6,281,016 | Short Ratio: 56.7% | Off-exchange volume (d
May 28, 2026
SEC
Allogene Therapeutics filed a DEFA14A supplementing its 2026 proxy statement to disclose the CEO transition from David C
DEFA14A — Impact 3/10
May 28, 2026
SEC
Allogene Therapeutics announced a CEO transition: David Chang, M.D., Ph.D., will step down as President and CEO effectiv
8-K — Impact 3/10
May 28, 2026
Press
Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as President and CEO effective
Impact 3/10
Apr 21, 2026
Press
Allogene Therapeutics announced regulatory clearance to expand its pivotal Phase 2 ALPHA3 trial of cemacabtagene anseged
Impact 7/10
Apr 21, 2026
Insider
Yoshiyama Annie sold 9,586 shares
SVP, Finance @ $2.31 ($22.1K)
Apr 15, 2026
SEC
Allogene Therapeutics announced a public offering of 87.5 million shares at $2.00 per share, raising approximately $175
8-K — Impact 5/10
Mar 31, 2026
Insider
Beneski Benjamin Machinas sold 2,867 shares
SVP, Chief Technical Officer @ $2.50 ($7.2K)
Price Targets
$8.49
+346.6% upside
Strong Buy
Current $1.90
Low $3.85
Median $9.00
High $14.00
10 analysts
$3.85
$14.00
Analyst Ratings
7Strong Buy
10Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 16, 2026 | JP Morgan | UPGRADE | Underweight → Neutral |
| Apr 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 15, 2026 | Jefferies | MAINTAIN | Buy → Buy |
| Apr 14, 2026 | Bernstein | MAINTAIN | Market Perform → Market Perform |
| Apr 14, 2026 | Argus Research | MAINTAIN | Market Perform → Market Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▲ +10.3% | $-0.17 — $-0.13 | 33% YoY | 5 |
| Next Q | $-0.14 ▲ +17.4% | $-0.17 — $-0.12 | 25% YoY | 5 |
| Current FY | $-0.61 ▲ +9.2% | $-0.66 — $-0.58 | 29% YoY | 5 |
| Next FY | $-0.68 ▲ +1.8% | $-1.00 — $-0.42 | -13% YoY | 6 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Allogene Therapeutics filed a DEFA14A supplementing its 2026 proxy statement to disclose the CEO transition from David C
May 28, 2026
NEUTRAL
8-K
3/10
Allogene Therapeutics announced a CEO transition: David Chang, M.D., Ph.D., will step down as President and CEO effectiv
May 28, 2026
NEUTRAL
Press
3/10
Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as President and CEO effective
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $46.6M | — |
| STATE STREET CORP | $21.1M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.9M | — |
| CITADEL ADVISORS LLC | $16.6M | ADD |
| TWO SIGMA INVESTMENTS, LP | $13.1M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 21, 2026 | Yoshiyama Annie | SELL | $22.1K |
| Mar 31, 2026 | Beneski Benjamin | SELL | $7.2K |
| Mar 16, 2026 | Beneski Benjamin | SELL | $11.9K |
| Mar 16, 2026 | Chang David | SELL | $118.0K |
| Mar 2, 2026 | Beneski Benjamin | SELL | $18.5K |
50 institutional holders with $198.8M total value (81,575,991 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 25 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 19,091,095 | $46.6M | 23.4% | — |
| 2 | STATE STREET CORP | 8,660,306 | $21.1M | 10.6% | DOUBLED +213.6% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 6,921,350 | $16.9M | 8.5% | — |
| 4 | CITADEL ADVISORS LLC | 6,793,620 | $16.6M | 8.3% | ADD +36.3% |
| 5 | TWO SIGMA INVESTMENTS, LP | 5,375,456 | $13.1M | 6.6% | DOUBLED +109.7% |
| 6 | Woodline Partners LP | 3,501,078 | $8.5M | 4.3% | — |
| 7 | MARSHALL WACE, LLP | 3,447,984 | $8.4M | 4.2% | DOUBLED +1107.4% |
| 8 | GOLDMAN SACHS GROUP INC | 2,766,244 | $6.7M | 3.4% | — |
| 9 | D. E. Shaw & Co., Inc. | 2,763,776 | $6.7M | 3.4% | DOUBLED +176.6% |
| 10 | Nuveen, LLC | 2,315,092 | $5.6M | 2.8% | DOUBLED +751.1% |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 2,139,328 | $5.2M | 2.6% | ADD +73.3% |
| 12 | BANK OF AMERICA CORP /DE/ | 2,134,473 | $5.2M | 2.6% | DOUBLED +111.9% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,694,112 | $4.1M | 2.1% | — |
| 14 | FMR LLC | 1,589,830 | $3.9M | 2.0% | DOUBLED +103.4% |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,396,533 | $3.4M | 1.7% | — |
| 16 | DIMENSIONAL FUND ADVISORS LP | 1,201,655 | $2.9M | 1.5% | ADD +25.5% |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 1,182,816 | $2.9M | 1.5% | — |
| 18 | VANGUARD FIDUCIARY TRUST CO | 1,091,809 | $2.7M | 1.3% | — |
| 19 | MORGAN STANLEY | 998,845 | $2.4M | 1.2% | ADD +42.1% |
| 20 | Invesco Ltd. | 684,519 | $1.7M | 0.8% | ADD +32.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 2,761,400 | 8,660,306 | +213.6% | $21.1M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 285,561 | 3,447,984 | +1107.4% | $8.4M | 2026-Q1 |
| Nuveen, LLC | DOUBLED | 272,007 | 2,315,092 | +751.1% | $5.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,007,328 | 2,134,473 | +111.9% | $5.2M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 957,816 | 1,201,655 | +25.5% | $2.9M | 2026-Q1 |
| MORGAN STANLEY | ADD | 703,138 | 998,845 | +42.1% | $2.4M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 484,622 | 654,180 | +35.0% | $1.6M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | ADD | 414,074 | 652,484 | +57.6% | $1.6M | 2026-Q1 |
| Mitsubishi UFJ Asset Management Co., Ltd. | DOUBLED | 138,900 | 428,700 | +208.6% | $1.0M | 2026-Q1 |
| HSBC HOLDINGS PLC | ADD | 148,136 | 260,404 | +75.8% | $638.0K | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 103,740 | 221,335 | +113.4% | $540.1K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 40,041 | 182,344 | +355.4% | $444.9K | 2026-Q1 |
| Cerity Partners LLC | ADD | 97,909 | 157,235 | +60.6% | $383.7K | 2026-Q1 |
| CWM, LLC | DOUBLED | 62,738 | 147,157 | +134.6% | $359.1K | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 39,781 | 113,964 | +186.5% | $278.1K | 2026-Q1 |
| Mariner, LLC | DOUBLED | 36,493 | 108,722 | +197.9% | $265.2K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 55,583 | 96,114 | +72.9% | $238.4K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 71,451 | 92,886 | +30.0% | $222.3K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 53,101 | 89,938 | +69.4% | $219.4K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 67,788 | 88,523 | +30.6% | $216.0K | 2026-Q1 |
| MetLife Investment Management, LLC | DOUBLED | 34,823 | 73,717 | +111.7% | $179.9K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 7,896 | 13,868 | +75.6% | $33.8K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 1,914 | 7,898 | +312.6% | $19.3K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 3,209,275 | 5,380,902 | +67.7% | $13.1K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 2,768 | 4,014 | +45.0% | $9.8K | 2026-Q1 |
7 unique insiders with 25 transactions. Net insider value: -$515.2K ($0.00 bought, $515.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 21, 2026 | Yoshiyama Annie | SVP, Finance | SELL | 9,586 | $2.31 | $22.1K |
| Mar 31, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | SELL | 2,867 | $2.50 | $7.2K |
| Mar 16, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | SELL | 4,835 | $2.47 | $11.9K |
| Mar 16, 2026 | Chang David D | President and CEO | SELL | 47,763 | $2.47 | $118.0K |
| Mar 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | SELL | 7,132 | $2.60 | $18.5K |
| Feb 2, 2026 | Douglas Earl Martin | SVP, General Counsel | SELL | 22,900 | $1.76 | $40.3K |
| Feb 2, 2026 | Douglas Earl Martin | SVP, General Counsel | AWARD | 539,072 | — | — |
| Feb 2, 2026 | Douglas Earl Martin | SVP, General Counsel | AWARD | 152,480 | — | — |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | SELL | 7,549 | $1.73 | $13.1K |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | AWARD | 373,757 | — | — |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | AWARD | 105,720 | — | — |
| Feb 2, 2026 | Roberts Zachary | EVP of R&D | SELL | 35,700 | $1.77 | $63.2K |
| Feb 2, 2026 | Roberts Zachary | EVP of R&D | AWARD | 718,763 | — | — |
| Feb 2, 2026 | Roberts Zachary | EVP of R&D | AWARD | 203,307 | — | — |
| Feb 2, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | SELL | 24,001 | $1.76 | $42.2K |
| Feb 2, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | AWARD | 539,072 | — | — |
| Feb 2, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | AWARD | 152,480 | — | — |
| Feb 2, 2026 | Chang David D | President and CEO | SELL | 95,269 | $1.80 | $171.5K |
| Feb 2, 2026 | Chang David D | President and CEO | AWARD | 1,387,931 | — | — |
| Feb 2, 2026 | Chang David D | President and CEO | AWARD | 392,586 | — | — |
| Feb 2, 2026 | Yoshiyama Annie | SVP, Finance | SELL | 4,167 | $1.72 | $7.2K |
| Feb 2, 2026 | Yoshiyama Annie | SVP, Finance | AWARD | 179,691 | — | — |
| Feb 2, 2026 | Yoshiyama Annie | SVP, Finance | AWARD | 50,827 | — | — |
| Feb 2, 2026 | Belldegrun Arie | Director | AWARD | 929,913 | — | — |
| Feb 2, 2026 | Belldegrun Arie | Director | AWARD | 263,033 | — | — |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 4 neutral. Avg impact: 5.1/10.
NEUTRAL
DEFA14A
3/10
Allogene Therapeutics filed a DEFA14A supplementing its 2026 proxy statement to disclose the CEO tra
May 28, 2026
NEUTRAL
8-K
3/10
Allogene Therapeutics announced a CEO transition: David Chang, M.D., Ph.D., will step down as Presid
May 28, 2026
NEUTRAL
8-K
5/10
Allogene Therapeutics announced a public offering of 87.5 million shares at $2.00 per share, raising
Apr 15, 2026
BEARISH
424B5
7/10
Allogene Therapeutics is raising $175 million through an 87.5 million share public offering at $2.00
Apr 15, 2026
MIXED
424B5
6/10
Allogene Therapeutics is raising $175 million through a public offering of common stock, with procee
Apr 13, 2026
BEARISH
8-K
7/10
Allogene Therapeutics announced a proposed underwritten public offering of its common stock and susp
Apr 13, 2026
BULLISH
8-K
7/10
Allogene Therapeutics announced positive interim futility analysis from its Phase 2 ALPHA3 trial of
Apr 13, 2026
NEUTRAL
CLUSTER
3/10
Two senior executives at Allogene Therapeutics, including the CEO and Chief Technical Officer, sold
Mar 18, 2026
NEUTRAL
3/10
Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as Presiden
May 28, 2026
BULLISH
7/10
Allogene Therapeutics announced regulatory clearance to expand its pivotal Phase 2 ALPHA3 trial of c
Apr 21, 2026
BULLISH
7/10
Allogene Therapeutics announced pre-clinical data published in Nature Communications showing that it
Apr 15, 2026
BEARISH
6/10
Allogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per sha
Apr 15, 2026
BEARISH
6/10
Allogene Therapeutics announced a proposed public offering of $175 million in common stock, with und
Apr 13, 2026
NEUTRAL
5/10
Allogene Therapeutics reported Q4 and full-year 2025 financial results, highlighting a reduced net l
Mar 12, 2026
NEUTRAL
3/10
Allogene Therapeutics announced it will report its fourth quarter and full year 2025 financial resul
Mar 2, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 20 analysts: 7 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.49 mean target
+346.6% upside
Strong Buy (1.54)
$3.85 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $1.90 |
| Target Low | $3.85 |
| Target Mean | $8.49 |
| Target Median | $9.00 |
| Target High | $14.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.54) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.17 | $-0.13 | 33.3% | +10.3% | 2↑ 0↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-0.14 | $-0.17 | $-0.12 | 25.3% | +17.4% | 2↑ 0↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-0.61 | $-0.66 | $-0.58 | 28.8% | +9.2% | 2↑ 1↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-0.68 | $-1.00 | $-0.42 | -12.5% | +1.8% | 1↑ 3↓ | $0.0B | 216118.5% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.148 | |
| 7d ago | $-0.157 | +0.009 |
| 30d ago | $-0.165 | +0.017 |
| 60d ago | $-0.160 | +0.012 |
| 90d ago | $-0.222 | +0.074 |
10 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 16, 2026 | JP Morgan | UPGRADE | Underweight | Neutral |
| Apr 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 15, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Apr 14, 2026 | Argus Research | MAINTAIN | Market Perform | Market Perform |
| Apr 14, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 14, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 9, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% | |
| May 1, 2026 | 7 | 11 | 2 | 1 | 0 | 86% | |
| Apr 1, 2026 | 7 | 11 | 2 | 1 | 0 | 86% | |
| Mar 1, 2026 | 7 | 11 | 2 | 1 | 0 | 86% | |
| Feb 1, 2026 | 7 | 11 | 2 | 1 | 0 | 86% | |
| Jan 1, 2026 | 7 | 9 | 3 | 1 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
short_volume
Short Volume: ALLO — 56.7% short (3.6M / 6.3M)
Short: 3,559,817 | Exempt: 38,492 | TRF Vol: 6,281,016 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: ALLO — 58.2% short (2.1M / 3.6M)
Short: 2,092,608 | Exempt: 18,355 | TRF Vol: 3,594,407 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: ALLO — 66.9% short (3.4M / 5.0M)
Short: 3,373,679 | Exempt: 3,157 | TRF Vol: 5,044,188 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: ALLO — 55.3% short (2.2M / 4.0M)
Short: 2,222,776 | Exempt: 9,272 | TRF Vol: 4,020,144 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: ALLO — 74.0% short (4.2M / 5.7M)
Short: 4,204,325 | Exempt: 19,369 | TRF Vol: 5,680,616 | Short Ratio: 74.0% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: ALLO — 62.1% short (3.1M / 4.9M)
Short: 3,071,387 | Exempt: 5,946 | TRF Vol: 4,942,046 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: ALLO — 64.4% short (3.0M / 4.7M)
Short: 3,045,660 | Exempt: 36,741 | TRF Vol: 4,729,057 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: ALLO — 67.5% short (3.8M / 5.6M)
Short: 3,751,841 | Exempt: 8,774 | TRF Vol: 5,560,330 | Short Ratio: 67.5% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ALLO — 63.8% short (3.0M / 4.7M)
Short: 2,989,581 | Exempt: 5,148 | TRF Vol: 4,689,350 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
May 28, 2026
leadership
Allogene Therapeutics Announces Planned CEO Succession
<p align="left">SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechno
May 26, 2026
other
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
<p>SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company
May 22, 2026
short_volume
Short Volume: ALLO — 56.3% short (1.4M / 2.5M)
Short: 1,415,112 | Exempt: 4,024 | TRF Vol: 2,515,297 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: ALLO — 63.9% short (1.6M / 2.4M)
Short: 1,562,611 | Exempt: 4,381 | TRF Vol: 2,446,596 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: ALLO — 57.2% short (2.3M / 4.0M)
Short: 2,297,360 | Exempt: 24,493 | TRF Vol: 4,016,122 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ALLO — 57.2% short (2.4M / 4.2M)
Short: 2,409,948 | Exempt: 19,370 | TRF Vol: 4,210,440 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Phase Phase 2 — TERMINATED